SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
冷冷
Lv7
4710 积分
2022-07-26 加入
最近求助
最近应助
互助留言
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
4天前
已完结
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
4天前
已完结
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
5天前
已完结
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
10天前
已完结
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study
10天前
已完结
Pembrolizumab Plus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up
21天前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
21天前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
26天前
已完结
2022年中国恶性肿瘤流行情况分析
1个月前
已完结
Cancer incidence and mortality in China, 2022
1个月前
已完结
没有进行任何应助
感谢,点赞
4天前
速度真快,点赞
4天前
感谢
5天前
速度真快
10天前
速度真快
10天前
点赞,感谢
21天前
速度真快,帮大忙了
21天前
点赞,速度真快
26天前
速度真快,点赞
1个月前
请问有中文版本吗
1个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论